ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $951,083 | -16.9% | 970,238 | +17.8% | 0.00% | – |
| Q2 2023 | $1,144,674 | -45.5% | 823,507 | -37.7% | 0.00% | – |
| Q1 2023 | $2,100,099 | +26240.1% | 1,320,817 | +3.2% | 0.00% | -100.0% |
| Q4 2022 | $7,973 | -99.9% | 1,279,924 | +13.5% | 0.00% | 0.0% |
| Q3 2022 | $7,554,000 | +8.4% | 1,127,580 | +2.9% | 0.00% | 0.0% |
| Q2 2022 | $6,966,000 | +35.1% | 1,095,412 | -1.4% | 0.00% | 0.0% |
| Q1 2022 | $5,155,000 | +24.5% | 1,111,047 | +34.2% | 0.00% | – |
| Q4 2021 | $4,140,000 | +0.5% | 828,196 | +142.3% | 0.00% | -100.0% |
| Q3 2021 | $4,119,000 | -56.8% | 341,871 | -24.2% | 0.00% | 0.0% |
| Q2 2021 | $9,537,000 | -24.2% | 450,965 | +0.5% | 0.00% | -50.0% |
| Q1 2021 | $12,584,000 | +18.7% | 448,663 | +10.0% | 0.00% | 0.0% |
| Q4 2020 | $10,604,000 | -28.3% | 407,872 | +2.5% | 0.00% | -33.3% |
| Q3 2020 | $14,792,000 | -25.8% | 397,961 | +2.5% | 0.00% | -25.0% |
| Q2 2020 | $19,929,000 | +70.2% | 388,417 | +4.6% | 0.00% | +33.3% |
| Q1 2020 | $11,710,000 | -71.6% | 371,416 | -46.3% | 0.00% | -25.0% |
| Q4 2019 | $41,272,000 | +218.8% | 692,152 | +96.0% | 0.00% | +33.3% |
| Q3 2019 | $12,947,000 | -20.3% | 353,175 | +1.2% | 0.00% | -25.0% |
| Q2 2019 | $16,237,000 | +37.2% | 349,046 | +18.4% | 0.00% | +33.3% |
| Q1 2019 | $11,832,000 | -53.3% | 294,714 | -46.5% | 0.00% | -25.0% |
| Q4 2018 | $25,336,000 | +123.9% | 550,820 | +116.0% | 0.00% | +33.3% |
| Q3 2018 | $11,314,000 | +34.5% | 255,007 | +18.8% | 0.00% | 0.0% |
| Q2 2018 | $8,411,000 | -34.9% | 214,625 | +20.1% | 0.00% | -25.0% |
| Q1 2018 | $12,928,000 | +12.8% | 178,743 | +2.7% | 0.00% | 0.0% |
| Q4 2017 | $11,461,000 | +29.5% | 174,080 | -1.4% | 0.00% | +33.3% |
| Q3 2017 | $8,851,000 | +34.8% | 176,611 | +24.5% | 0.00% | 0.0% |
| Q2 2017 | $6,565,000 | +36.2% | 141,875 | +3.9% | 0.00% | +50.0% |
| Q1 2017 | $4,820,000 | +198.3% | 136,521 | +5.8% | 0.00% | +100.0% |
| Q4 2016 | $1,616,000 | +5.1% | 129,084 | +16.2% | 0.00% | 0.0% |
| Q3 2016 | $1,537,000 | +42.2% | 111,046 | +1.4% | 0.00% | 0.0% |
| Q2 2016 | $1,081,000 | -40.4% | 109,473 | +1.9% | 0.00% | 0.0% |
| Q1 2016 | $1,815,000 | -10.5% | 107,392 | +17.8% | 0.00% | 0.0% |
| Q4 2015 | $2,029,000 | -2.6% | 91,184 | +3.2% | 0.00% | 0.0% |
| Q3 2015 | $2,083,000 | -73.3% | 88,322 | -7.3% | 0.00% | -75.0% |
| Q2 2015 | $7,790,000 | -4.1% | 95,289 | +8.6% | 0.00% | -20.0% |
| Q1 2015 | $8,121,000 | +272.5% | 87,709 | +62.7% | 0.01% | +400.0% |
| Q4 2014 | $2,180,000 | +197.4% | 53,923 | +79.9% | 0.00% | – |
| Q3 2014 | $733,000 | +54.6% | 29,974 | +0.2% | 0.00% | – |
| Q2 2014 | $474,000 | +3.3% | 29,929 | -1.6% | 0.00% | – |
| Q1 2014 | $459,000 | +9.8% | 30,418 | -0.2% | 0.00% | – |
| Q4 2013 | $418,000 | -26.9% | 30,467 | +0.4% | 0.00% | – |
| Q3 2013 | $572,000 | – | 30,335 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |